These enzymatic systems play a crucial role in AD- and PD-associated neurodegeneration, as revealed by the neuroprotection achieved by the pharmacological or genetic inhibition of NOX2 or iNOS reported in animal models of AD [45,46] and PD [47,48,49,50]. Here, CYBB is linked to Alzheimer disease.